Table 3.

Bivariate analysis for Gender, Age, and Race/Ethnicity

	Gender			Age				Race/Ethnicity
Medication Class	Male (%) N = 1381	Female (%) N = 1564	p	65–69 (%) N = 1221	70–74 (%) N = 1024	75–79 (%) N = 700	p	White non-Hispanic (%) N = 2523	Black, Non-Hispanic (%) N = 207	Asian (%) N = 65	Other, Non-Hispanic (%)* N = 67	Hispanic (%) N = 79	P
Antihistamine	10.6	14.1	<.01	13.1	11.6	12.7	.56	12.7	11.1	9.2	17.9	8.9	.19
Anti-infective agents	9.3	10.4	.386	9.8	9.2	11.0	.46	10.0	9.7	4.6	11.9	8.9	.26
Anti-neoplastic agents	2.5	5.0	<.01	3.7	4.1	3.6	.82	3.9	3.4	1.5	4.5	2.5	.94
Autonomic	26.8%	17.3%	<.01	20.3%	22.6%	23.1%	.26	21.3%	25.1%	18.5%	28.4%	25.3%	.21
Blood Formation, Coagulation	17.9	9.1	<.01	9.6	14.1	18.4	<.01	13.3	14.5	13.8	9.0	12.7	.83
Cardiovascular	78.8	68.9	<.01	68.1	74.9	81.1	<.01	73.2	79.2	72.3	71.6	70.9	.58
CNS agents	71.0	69.6	.408	67.2	72.9	71.7	<.01	70.9	67.6	46.2	79.1	65.8	<.01
EENT	24.0	24.1	.968	21.8	24.6	27.3	.02	23.8	25.6	27.7	26.9	24.1	.84
Electrolytic	41.1	62.5	<.01	51.3	50.6	57.3	.01	52.5	61.8	44.6	44.8	41.8	.02
Gastrointestinal drugs	30.6	32.4	.32	29.5	32.3	34.0	.10	31.6	31.9	23.1	29.9	38.0	.45
Hormones and synthetic substitutes	38.2	50.1	<.01	43.6	44.4	46.3	.51	44.5	45.4	40.0	50.7	43.0	.62
Respiratory tract	3.0	4.1	.13	2.9	4.1	4.1	.12	3.4	4.8	7.7	3.0	5.1	.14
Skin and mucous membrane agents	18.0	15.0	.03	13.3	18.7	18.4	<.01	16.4	17.9	13.8	14.9	16.5	.92
Smooth Muscle Relaxants	1.9	4.0	<.01	2.0	3.3	4.4	<.01	3.0	2.9	1.5	3.0	6.3	.17
Vitamins	58.7	70.2	<.01	64.0	63.1	68.6	.05	65.6	60.9	50.8	65.7	63.3	.24
Not classified	32.1	38.7	<.01	33.4	36.7	37.7	.11	36.6	30.4	32.3	35.8	27.8	.22
Miscellaneous agents	15.7	10.2	<.01	11.1	13.1	15.3	.03	13.0	11.1	12.3	16.4	10.1	.79